Literature DB >> 8079856

MR arthrography of the shoulder with gadopentetate dimeglumine: influence of concentration, iodinated contrast material, and time on signal intensity.

L Kopka1, M Funke, U Fischer, D Keating, J Oestmann, E Grabbe.   

Abstract

OBJECTIVE: MR arthrography of the shoulder with gadopentetate dimeglumine has been proved to be valuable in the diagnosis of injuries of the rotator cuff and glenoid labrum. To date, no standard protocol for the concentration of gadopentetate dimeglumine and the volume of iodinated contrast material used for intraarticular injection exists. This study compared the intraarticular signal intensities achieved with three different MR arthrography protocols with respect to the volume of iodinated contrast material, the concentration of gadopentetate dimeglumine, and the interval between injection of contrast material and the MR study. SUBJECTS AND METHODS: MR arthrography was performed with three different protocols in 38 patients (26 men, 12 women). Patients examined with protocol 1 received an intraarticular injection of 5 ml of iotrolan and 5 ml of a 5 mmol/l solution of gadopentetate dimeglumine, resulting in a gadopentetate dimeglumine concentration of 2.5 mmol/l. Patients in protocol 2 received only 0.5 ml of iotrolan plus 12 ml of a 10 mmol/l solution of gadopentetate dimeglumine, leading to a 10 mmol/l concentration. The interval between injection and MR imaging for patients in protocols 1 and 2 was 30-45 min. Patients in protocol 3 received an intraarticular injection of 10 ml iotrolan and 1 ml of a 500 mmol/l solution of gadopentetate dimeglumine, resulting in an intraarticular concentration of gadopentetate dimeglumine of 45 mmol/l. MR examinations were performed between 20 and 360 min after administration of contrast material. Patients in protocol 3 had additional conventional and CT arthrography within 30 min after injection. The contrast-to-noise ratio of the intraarticular signal intensity was calculated for all protocols.
RESULTS: The contrast-to-noise ratio (mean +/- SD) was 22.7 +/- 7.4 for the 2.5 mmol/l solution (protocol 1), 47.5 +/- 11.9 for the 10 mmol/l solution (protocol 2), and 9.9 +/- 3.1 for the 45 mmol/l solution (protocol 3) within 1 hr after injection. For protocol 3, an increase in contrast-to-noise ratio was observed after 90-180 min (53.5 +/- 12.7), followed by a decrease in contrast-to-noise ratio after 180 min (17.1 +/- 8.2). The image quality of conventional, CT, and MR arthrography (90-180 min after injection) was good in all cases of protocol 3.
CONCLUSION: For MR arthrography performed within 1 hr after injection, protocol 2 is sufficient. The optimal time frame for protocol 3 is between 1.5 and 3 hr after joint puncture. Protocol 3 allows the prior performance of conventional and CT arthrography. Therefore, the addition of 1 ml of a 500 mmol/l solution of gadopentetate dimeglumine to 10 ml of iodinated contrast material is advisable if a subsequent MR study is anticipated.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8079856     DOI: 10.2214/ajr.163.3.8079856

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  11 in total

1.  Ultrasound guidance to perform intra-articular injection of gadolinium-based contrast material for magnetic resonance arthrography as an alternative to fluoroscopy: the time is now.

Authors:  Carmelo Messina; Giuseppe Banfi; Alberto Aliprandi; Giovanni Mauri; Francesco Secchi; Francesco Sardanelli; Luca Maria Sconfienza
Journal:  Eur Radiol       Date:  2015-08-08       Impact factor: 5.315

Review 2.  Technical errors in MR arthrography.

Authors:  Juerg Hodler
Journal:  Skeletal Radiol       Date:  2007-05-26       Impact factor: 2.199

Review 3.  MR arthrography made simple: indications and techniques.

Authors:  John D MacKenzie
Journal:  Pediatr Radiol       Date:  2008-05

4.  Direct shoulder magnetic resonance arthrography for superior labral anterior-to-posterior (SLAP) and Bankart lesions: investigation into the appropriate dose and level of local anesthesia.

Authors:  Sun Hwa Lee; Seong Jong Yun; Hyeon Hwan Jo; Dong Hyeon Kim; Jae Gwang Song; Yong Sung Park
Journal:  Br J Radiol       Date:  2017-07-27       Impact factor: 3.039

5.  Freehand direct arthrography of the shoulder using near real-time guidance in an open 1.0-T MRI scanner.

Authors:  Christian Wybranski; Ilya Adamchic; Friedrich-Wilhelm Röhl; Jens Ricke; Frank Fischbach; Katharina Fischbach
Journal:  Skeletal Radiol       Date:  2016-10-22       Impact factor: 2.199

6.  MR arthrography of the shoulder: comparison of low-field (0.2 T) vs high-field (1.5 T) imaging.

Authors:  R Loew; K F Kreitner; M Runkel; J Zoellner; M Thelen
Journal:  Eur Radiol       Date:  2000       Impact factor: 5.315

7.  Diagnostic performance of shoulder magnetic resonance arthrography for labral tears having surgery as reference: comparison of high-resolution isotropic 3D sequence (THRIVE) with standard protocol.

Authors:  Sun Hwa Lee; Seong Jong Yun; Youngno Yoon
Journal:  Radiol Med       Date:  2018-03-26       Impact factor: 3.469

8.  In vitro chondrocyte toxicity following long-term, high-dose exposure to Gd-DTPA and a novel cartilage-targeted MR contrast agent.

Authors:  Sharon Midura; Erika Schneider; Gerald M Rosen; Carl S Winalski; Ronald J Midura
Journal:  Skeletal Radiol       Date:  2016-11-04       Impact factor: 2.199

9.  Optimization of the contrast mixture ratio for simultaneous direct MR and CT arthrography: an in vitro study.

Authors:  Ja Young Choi; Heung Sik Kang; Sung Hwan Hong; Joon Woo Lee; Na Ra Kim; Woo Sun Jun; Sung Gyu Moon; Jung Ah Choi
Journal:  Korean J Radiol       Date:  2008 Nov-Dec       Impact factor: 3.500

10.  Gadolinium retention within multiple rat organs after intra-articular administration of gadolinium-based contrast agents.

Authors:  Michael D Ringler; Nicholas G Rhodes; Jennifer R Ayers-Ringler; Daniel R Jakaitis; Robert J McDonald; David F Kallmes; Jennifer S McDonald
Journal:  Skeletal Radiol       Date:  2021-01-06       Impact factor: 2.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.